Martin Duddy

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis

Martin Duddy, Masaaki Niino, Femina Adatia et al. · The Journal of Immunology · 2007 · 637 citations · Full text

Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?

Martin Duddy, Andrea Alter, Amit Bar‐Or · The Journal of Immunology · 2004 · 358 citations

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease

Shahd Hamid, Dan Whittam, Mariyam Saviour et al. · JAMA Neurology · 2017 · 208 citations · Full text